Cargando…
Effect of transcutaneous auricular vagus nerve stimulation on impaired glucose tolerance: a pilot randomized study
BACKGROUND: Impaired glucose tolerance (IGT) is a pre-diabetic state of hyperglycemia that is associated with insulin resistance, increased risk of type II diabetes, and cardiovascular pathology. Recently, investigators hypothesized that decreased vagus nerve activity may be the underlying mechanism...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4227038/ https://www.ncbi.nlm.nih.gov/pubmed/24968966 http://dx.doi.org/10.1186/1472-6882-14-203 |
_version_ | 1782343721416654848 |
---|---|
author | Huang, Feng Dong, Jianxun Kong, Jian Wang, Hongcai Meng, Hong Spaeth, Rosa B Camhi, Stephanie Liao, Xing Li, Xia Zhai, Xu Li, Shaoyuan Zhu, Bing Rong, Peijing |
author_facet | Huang, Feng Dong, Jianxun Kong, Jian Wang, Hongcai Meng, Hong Spaeth, Rosa B Camhi, Stephanie Liao, Xing Li, Xia Zhai, Xu Li, Shaoyuan Zhu, Bing Rong, Peijing |
author_sort | Huang, Feng |
collection | PubMed |
description | BACKGROUND: Impaired glucose tolerance (IGT) is a pre-diabetic state of hyperglycemia that is associated with insulin resistance, increased risk of type II diabetes, and cardiovascular pathology. Recently, investigators hypothesized that decreased vagus nerve activity may be the underlying mechanism of metabolic syndrome including obesity, elevated glucose levels, and high blood pressure. METHODS: In this pilot randomized clinical trial, we compared the efficacy of transcutaneous auricular vagus nerve stimulation (taVNS) and sham taVNS on patients with IGT. 72 participants with IGT were single-blinded and were randomly allocated by computer-generated envelope to either taVNS or sham taVNS treatment groups. In addition, 30 IGT adults were recruited as a control population and not assigned treatment so as to monitor the natural fluctuation of glucose tolerance in IGT patients. All treatments were self-administered by the patients at home after training at the hospital. Patients were instructed to fill in a patient diary booklet each day to describe any side effects after each treatment. The treatment period was 12 weeks in duration. Baseline comparison between treatment and control group showed no difference in weight, BMI, or measures of systolic blood pressure, diastolic blood pressure, fasting plasma glucose (FPG), 2-hour plasma glucose (2hPG), or glycosylated hemoglobin (HbAlc). RESULTS: 100 participants completed the study and were included in data analysis. Two female patients (one in the taVNS group, one in the sham taVNS group) dropped out of the study due to stimulation-evoked dizziness. The symptoms were relieved after stopping treatment. Compared with sham taVNS, taVNS significantly reduced the two-hour glucose tolerance (F(2) = 5.79, p = 0.004). In addition, we found that taVNS significantly decreased (F(1) = 4.21, p = 0.044) systolic blood pressure over time compared with sham taVNS. Compared with the no-treatment control group, patients receiving taVNS significantly differed in measures of FPG (F(2) = 10.62, p < 0.001), 2hPG F(2) = 25.18, p < 0.001) and HbAlc (F(1) = 12.79, p = 0.001) over the course of the 12 week treatment period. CONCLUSIONS: Our study suggests that taVNS is a promising, simple, and cost-effective treatment for IGT/ pre-diabetes with only slight risk of mild side-effects. |
format | Online Article Text |
id | pubmed-4227038 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-42270382014-11-12 Effect of transcutaneous auricular vagus nerve stimulation on impaired glucose tolerance: a pilot randomized study Huang, Feng Dong, Jianxun Kong, Jian Wang, Hongcai Meng, Hong Spaeth, Rosa B Camhi, Stephanie Liao, Xing Li, Xia Zhai, Xu Li, Shaoyuan Zhu, Bing Rong, Peijing BMC Complement Altern Med Research Article BACKGROUND: Impaired glucose tolerance (IGT) is a pre-diabetic state of hyperglycemia that is associated with insulin resistance, increased risk of type II diabetes, and cardiovascular pathology. Recently, investigators hypothesized that decreased vagus nerve activity may be the underlying mechanism of metabolic syndrome including obesity, elevated glucose levels, and high blood pressure. METHODS: In this pilot randomized clinical trial, we compared the efficacy of transcutaneous auricular vagus nerve stimulation (taVNS) and sham taVNS on patients with IGT. 72 participants with IGT were single-blinded and were randomly allocated by computer-generated envelope to either taVNS or sham taVNS treatment groups. In addition, 30 IGT adults were recruited as a control population and not assigned treatment so as to monitor the natural fluctuation of glucose tolerance in IGT patients. All treatments were self-administered by the patients at home after training at the hospital. Patients were instructed to fill in a patient diary booklet each day to describe any side effects after each treatment. The treatment period was 12 weeks in duration. Baseline comparison between treatment and control group showed no difference in weight, BMI, or measures of systolic blood pressure, diastolic blood pressure, fasting plasma glucose (FPG), 2-hour plasma glucose (2hPG), or glycosylated hemoglobin (HbAlc). RESULTS: 100 participants completed the study and were included in data analysis. Two female patients (one in the taVNS group, one in the sham taVNS group) dropped out of the study due to stimulation-evoked dizziness. The symptoms were relieved after stopping treatment. Compared with sham taVNS, taVNS significantly reduced the two-hour glucose tolerance (F(2) = 5.79, p = 0.004). In addition, we found that taVNS significantly decreased (F(1) = 4.21, p = 0.044) systolic blood pressure over time compared with sham taVNS. Compared with the no-treatment control group, patients receiving taVNS significantly differed in measures of FPG (F(2) = 10.62, p < 0.001), 2hPG F(2) = 25.18, p < 0.001) and HbAlc (F(1) = 12.79, p = 0.001) over the course of the 12 week treatment period. CONCLUSIONS: Our study suggests that taVNS is a promising, simple, and cost-effective treatment for IGT/ pre-diabetes with only slight risk of mild side-effects. BioMed Central 2014-06-26 /pmc/articles/PMC4227038/ /pubmed/24968966 http://dx.doi.org/10.1186/1472-6882-14-203 Text en Copyright © 2014 Huang et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Huang, Feng Dong, Jianxun Kong, Jian Wang, Hongcai Meng, Hong Spaeth, Rosa B Camhi, Stephanie Liao, Xing Li, Xia Zhai, Xu Li, Shaoyuan Zhu, Bing Rong, Peijing Effect of transcutaneous auricular vagus nerve stimulation on impaired glucose tolerance: a pilot randomized study |
title | Effect of transcutaneous auricular vagus nerve stimulation on impaired glucose tolerance: a pilot randomized study |
title_full | Effect of transcutaneous auricular vagus nerve stimulation on impaired glucose tolerance: a pilot randomized study |
title_fullStr | Effect of transcutaneous auricular vagus nerve stimulation on impaired glucose tolerance: a pilot randomized study |
title_full_unstemmed | Effect of transcutaneous auricular vagus nerve stimulation on impaired glucose tolerance: a pilot randomized study |
title_short | Effect of transcutaneous auricular vagus nerve stimulation on impaired glucose tolerance: a pilot randomized study |
title_sort | effect of transcutaneous auricular vagus nerve stimulation on impaired glucose tolerance: a pilot randomized study |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4227038/ https://www.ncbi.nlm.nih.gov/pubmed/24968966 http://dx.doi.org/10.1186/1472-6882-14-203 |
work_keys_str_mv | AT huangfeng effectoftranscutaneousauricularvagusnervestimulationonimpairedglucosetoleranceapilotrandomizedstudy AT dongjianxun effectoftranscutaneousauricularvagusnervestimulationonimpairedglucosetoleranceapilotrandomizedstudy AT kongjian effectoftranscutaneousauricularvagusnervestimulationonimpairedglucosetoleranceapilotrandomizedstudy AT wanghongcai effectoftranscutaneousauricularvagusnervestimulationonimpairedglucosetoleranceapilotrandomizedstudy AT menghong effectoftranscutaneousauricularvagusnervestimulationonimpairedglucosetoleranceapilotrandomizedstudy AT spaethrosab effectoftranscutaneousauricularvagusnervestimulationonimpairedglucosetoleranceapilotrandomizedstudy AT camhistephanie effectoftranscutaneousauricularvagusnervestimulationonimpairedglucosetoleranceapilotrandomizedstudy AT liaoxing effectoftranscutaneousauricularvagusnervestimulationonimpairedglucosetoleranceapilotrandomizedstudy AT lixia effectoftranscutaneousauricularvagusnervestimulationonimpairedglucosetoleranceapilotrandomizedstudy AT zhaixu effectoftranscutaneousauricularvagusnervestimulationonimpairedglucosetoleranceapilotrandomizedstudy AT lishaoyuan effectoftranscutaneousauricularvagusnervestimulationonimpairedglucosetoleranceapilotrandomizedstudy AT zhubing effectoftranscutaneousauricularvagusnervestimulationonimpairedglucosetoleranceapilotrandomizedstudy AT rongpeijing effectoftranscutaneousauricularvagusnervestimulationonimpairedglucosetoleranceapilotrandomizedstudy |